Session Information
-
WCLC 2021
2022 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA02 - RET and Novel Combinations of Osimertinib
- 09:30 - 10:30
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
-
+
MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
09:30 - 09:35 | Presenter: Shun Lu
- Abstract
Loading...
-
+
FP04 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
00:00 - 00:00 | Presenter: Jie Wang
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
P60.12 - Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC
00:00 - 00:00 | Presenter: Monica Motwani
- Abstract
Loading...
-
+
P70 - Tumor Biology and Systems Biology: Basic and Translational Science - Omics Analysis of Lung Cancer
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
-
+
P70.09 - NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.11 - Prevalence and Clinicopathological Characteristics of ARID1A Mutations in East Asian Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.13 - Different Types of ERBB3 Mutations in Chinese Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.14 - PRKDC Mutations Recurrently Found in Non-Small Cell Lung Cancer in East Asian Patients
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.15 - Mutational Subtypes and Prognosis of East Asian Non-Small-Cell Lung Cancer Harboring NF2 Mutations
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.16 - Epidemiological Study of FGFR3 Mutations Among Non-Small Cell Lung Cancer Patients in China
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.17 - Molecular Characteristics and Prognosis TERT Mutations in East Asian Non-Small-Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.18 - Distribution of GNAS Mutations in Chinese Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.19 - Clinicopathologic Characteristics of Patients With LRP1B Mutations in Chinese Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading...
-
+
OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers
- 09:30 - 10:30
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
- Moderators:Rina Hui
-
+
OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
09:30 - 09:40 | Presenter: David Carbone
- Abstract
Loading...
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- 22:15 - 23:45
- 9/11/2021
- Location: Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
- Moderators:Caicun Zhou, ChunXue Bai
-
+
WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
22:53 - 23:03 | Presenter: Jie Wang
- Abstract
Loading... -
+
WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
23:13 - 23:23 | Presenter: Shun Lu
- Abstract
Loading...
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
19:15 - 19:25 | Presenter: D. Ross Camidge
- Abstract
Loading...
